[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-21jDT63bomg6jIgqV5TmXs-0AfN9hN9VBOGIgG4rV4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Shanghai Changzheng Hospital",[4],124,false,58,5,2046643,46,49,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Multiple Myeloma",9,{"name":18,"count":19},"Colorectal Cancer",8,{"name":21,"count":9},"Diabetes",{"name":23,"count":24},"Thyroid Associated Ophthalmopathies",4,{"name":26,"count":24},"Diabetes Mellitus",{"name":28,"count":29},"Cirrhosis",3,{"name":31,"count":29},"Spinal Metastases",{"name":33,"count":29},"Immunotherapy",[35,40,45,50,55,59,64,69,74,79],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05585814","CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer","2024-10-01","Capecitabine",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04278222","Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)","2024-10-31","Anlotinib Plus Toripalimab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06156332","A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy","2025-01-28","surufatinib、serplulimab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06473493","The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension","2025-03","Alverine",{"nctId":56,"briefTitle":57,"date":58,"intervention":39},"NCT06881537","CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","2025-06-30",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05838131","Study of CT071 Injection in RRMM or PPCL","2025-07","Experimental: CAR-T cells",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07103980","Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial","2025-07-30","Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06696248","Carvedilol and Alverine in Portal Hypertension","2025-09-30","Carvedilol and alverine",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06847178","Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes","2025-10-31","Low-dose LC-Z300-01 twice daily in blinding",{"nctId":80,"briefTitle":81,"date":82,"intervention":54},"NCT06470386","The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis","2025-11",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,137,160,188,208,232,250,268,298,345,371,406,436,461,479,502,526,544,562,588,615,633,658,681,699,724,752,785,839,871,896,922,946,970,999,1017,1042,1065,1088,1111,1131,1156,1181,1203,1229,1247,1272,1299,1317,1344,1362,1380,1406,1432,1458,1483,1538,1562,1585,1611,1629,1647,1674,1692,1717,1735,1758,1785,1803,1821,1847,1869,1887,1913,1937,1965,1989,2018,2036,2054,2072,2094,2118,2143,2165],{"intervention":92,"totalTrials":29,"cells":93},"IBI311",{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":135},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":29,"soonestReadout":110},[105,117,127],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT07152340","The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.","RECRUITING",[88],"2027-04-30","2030-05-01","2025-04-10",64,[23],[92,116],"Glucocorticoids",{"nctId":118,"briefTitle":119,"status":108,"phases":120,"primaryCompletion":121,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":126},"NCT07152392","Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO",[88],"2027-07-01","2035-04-15","2025-04-15",50,[23],[92],{"nctId":128,"briefTitle":129,"status":108,"phases":130,"primaryCompletion":131,"completion":122,"start":123,"enrollment":132,"conditions":133,"interventions":134},"NCT07152366","Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.",[88],"2027-05-31",96,[23],[92,116],{"trials":136,"activeCount":96},[],{"intervention":116,"totalTrials":138,"cells":139},2,{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":158},{"trials":141,"activeCount":96},[],{"trials":143,"activeCount":96},[],{"trials":145,"activeCount":96},[],{"trials":147,"activeCount":96},[],{"trials":149,"activeCount":138,"soonestReadout":110},[150,154],{"nctId":106,"briefTitle":107,"status":108,"phases":151,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":152,"interventions":153},[88],[23],[92,116],{"nctId":128,"briefTitle":129,"status":108,"phases":155,"primaryCompletion":131,"completion":122,"start":123,"enrollment":132,"conditions":156,"interventions":157},[88],[23],[92,116],{"trials":159,"activeCount":96},[],{"intervention":54,"totalTrials":138,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":184,"NA":186},{"trials":163,"activeCount":96},[],{"trials":165,"activeCount":96},[],{"trials":167,"activeCount":96},[],{"trials":169,"activeCount":138,"soonestReadout":53},[170,179],{"nctId":80,"briefTitle":81,"status":171,"phases":172,"primaryCompletion":82,"completion":82,"start":173,"enrollment":174,"conditions":175,"interventions":177},"NOT_YET_RECRUITING",[86,87],"2024-06",178,[176],"Hypertension, Portal",[54,178],"Carvedilol",{"nctId":51,"briefTitle":52,"status":171,"phases":180,"primaryCompletion":53,"completion":53,"start":173,"enrollment":181,"conditions":182,"interventions":183},[86,87],30,[176],[54],{"trials":185,"activeCount":96},[],{"trials":187,"activeCount":96},[],{"intervention":73,"totalTrials":189,"cells":190},1,{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":204,"NA":206},{"trials":192,"activeCount":96},[],{"trials":194,"activeCount":96},[],{"trials":196,"activeCount":96},[],{"trials":198,"activeCount":189,"soonestReadout":72},[199],{"nctId":70,"briefTitle":71,"status":171,"phases":200,"primaryCompletion":72,"completion":72,"start":201,"enrollment":181,"conditions":202,"interventions":203},[86,87],"2024-11-15",[176],[73],{"trials":205,"activeCount":96},[],{"trials":207,"activeCount":96},[],{"intervention":78,"totalTrials":189,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":228,"NA":230},{"trials":211,"activeCount":96},[],{"trials":213,"activeCount":96},[],{"trials":215,"activeCount":96},[],{"trials":217,"activeCount":189,"soonestReadout":77},[218],{"nctId":75,"briefTitle":76,"status":171,"phases":219,"primaryCompletion":77,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":225},[86,87],"2025-11-30","2025-03-01",60,[21,224],"Type 2 Diabetes",[78,226,227],"High-dose LC-Z300-01 twice daily in blinding","High-dose LCZ300-1 twice daily in open-label",{"trials":229,"activeCount":96},[],{"trials":231,"activeCount":96},[],{"intervention":226,"totalTrials":189,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":246,"NA":248},{"trials":235,"activeCount":96},[],{"trials":237,"activeCount":96},[],{"trials":239,"activeCount":96},[],{"trials":241,"activeCount":189,"soonestReadout":77},[242],{"nctId":75,"briefTitle":76,"status":171,"phases":243,"primaryCompletion":77,"completion":220,"start":221,"enrollment":222,"conditions":244,"interventions":245},[86,87],[21,224],[78,226,227],{"trials":247,"activeCount":96},[],{"trials":249,"activeCount":96},[],{"intervention":227,"totalTrials":189,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":264,"NA":266},{"trials":253,"activeCount":96},[],{"trials":255,"activeCount":96},[],{"trials":257,"activeCount":96},[],{"trials":259,"activeCount":189,"soonestReadout":77},[260],{"nctId":75,"briefTitle":76,"status":171,"phases":261,"primaryCompletion":77,"completion":220,"start":221,"enrollment":222,"conditions":262,"interventions":263},[86,87],[21,224],[78,226,227],{"trials":265,"activeCount":96},[],{"trials":267,"activeCount":96},[],{"intervention":178,"totalTrials":138,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":282,"NA":284},{"trials":271,"activeCount":96},[],{"trials":273,"activeCount":96},[],{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":189,"soonestReadout":82},[278],{"nctId":80,"briefTitle":81,"status":171,"phases":279,"primaryCompletion":82,"completion":82,"start":173,"enrollment":174,"conditions":280,"interventions":281},[86,87],[176],[54,178],{"trials":283,"activeCount":96},[],{"trials":285,"activeCount":96},[286],{"nctId":287,"briefTitle":288,"status":289,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT03195634","WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis","UNKNOWN",[],"2018-03","2018-12","2017-06",80,[296,28],"Portal Hypertension",[178],{"intervention":39,"totalTrials":29,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":339,"PHASE4":341,"NA":343},{"trials":301,"activeCount":96},[],{"trials":303,"activeCount":96},[],{"trials":305,"activeCount":29,"soonestReadout":38},[306,316,330],{"nctId":36,"briefTitle":37,"status":108,"phases":307,"primaryCompletion":38,"completion":308,"start":309,"enrollment":181,"conditions":310,"interventions":312},[86],"2028-05-01","2023-05-01",[311],"Locally Advanced Colorectal Cancer",[39,313,314,315],"Oxaliplatin","Bevacizumab","Pembrolizumab",{"nctId":317,"briefTitle":318,"status":171,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":327},"NCT07621484","HIPEC Priming Followed by Serplulimab Plus SOX\u002FXELOX in Locally Advanced Gastric Cancer",[86],"2028-05-09","2026-05-10",48,[324,325,326],"Locally Advanced Gastric Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[328,329,39,313],"Serplulimab","S-1",{"nctId":56,"briefTitle":57,"status":108,"phases":331,"primaryCompletion":58,"completion":332,"start":333,"enrollment":334,"conditions":335,"interventions":337},[86],"2028-06-30","2024-06-01",15,[336],"Locally Recurrent Colorectal Cancer",[39,313,314,338],"Tislelizumab",{"trials":340,"activeCount":96},[],{"trials":342,"activeCount":96},[],{"trials":344,"activeCount":96},[],{"intervention":313,"totalTrials":29,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":348,"activeCount":96},[],{"trials":350,"activeCount":96},[],{"trials":352,"activeCount":29,"soonestReadout":38},[353,357,361],{"nctId":36,"briefTitle":37,"status":108,"phases":354,"primaryCompletion":38,"completion":308,"start":309,"enrollment":181,"conditions":355,"interventions":356},[86],[311],[39,313,314,315],{"nctId":317,"briefTitle":318,"status":171,"phases":358,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":359,"interventions":360},[86],[324,325,326],[328,329,39,313],{"nctId":56,"briefTitle":57,"status":108,"phases":362,"primaryCompletion":58,"completion":332,"start":333,"enrollment":334,"conditions":363,"interventions":364},[86],[336],[39,313,314,338],{"trials":366,"activeCount":96},[],{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":96},[],{"intervention":314,"totalTrials":29,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":400,"PHASE4":402,"NA":404},{"trials":374,"activeCount":96},[],{"trials":376,"activeCount":96},[],{"trials":378,"activeCount":138,"soonestReadout":38},[379,383,396],{"nctId":36,"briefTitle":37,"status":108,"phases":380,"primaryCompletion":38,"completion":308,"start":309,"enrollment":181,"conditions":381,"interventions":382},[86],[311],[39,313,314,315],{"nctId":384,"briefTitle":385,"status":289,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT05588297","Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR\u002FMSS Colorectal Cancer Liver Metastases",[86],"2023-03","2025-10","2022-10",12,[392],"Colorectal Cancer Liver Metastases",[394,314,395],"CapOx","Nivolumab",{"nctId":56,"briefTitle":57,"status":108,"phases":397,"primaryCompletion":58,"completion":332,"start":333,"enrollment":334,"conditions":398,"interventions":399},[86],[336],[39,313,314,338],{"trials":401,"activeCount":96},[],{"trials":403,"activeCount":96},[],{"trials":405,"activeCount":96},[],{"intervention":338,"totalTrials":138,"cells":407},{"EARLY_PHASE1":408,"PHASE1":422,"PHASE2":424,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":409,"activeCount":189,"soonestReadout":414},[410],{"nctId":411,"briefTitle":412,"status":171,"phases":413,"primaryCompletion":414,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":420},"NCT07389187","Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[84],"2026-12","2028-06","2026-02",10,[419],"mCRPC",[338,421],"Standard Androgen Deprivation Therapy",{"trials":423,"activeCount":96},[],{"trials":425,"activeCount":189,"soonestReadout":58},[426],{"nctId":56,"briefTitle":57,"status":108,"phases":427,"primaryCompletion":58,"completion":332,"start":333,"enrollment":334,"conditions":428,"interventions":429},[86],[336],[39,313,314,338],{"trials":431,"activeCount":96},[],{"trials":433,"activeCount":96},[],{"trials":435,"activeCount":96},[],{"intervention":437,"totalTrials":189,"cells":438},"Prednisone",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":440,"activeCount":96},[],{"trials":442,"activeCount":96},[],{"trials":444,"activeCount":189,"soonestReadout":449},[445],{"nctId":446,"briefTitle":447,"status":108,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT06078969","Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence",[86],"2027-09-30","2023-11-04",118,[453],"Langerhans Cell Histiocytosis of Bone",[437],{"trials":456,"activeCount":96},[],{"trials":458,"activeCount":96},[],{"trials":460,"activeCount":96},[],{"intervention":315,"totalTrials":189,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":464,"activeCount":96},[],{"trials":466,"activeCount":96},[],{"trials":468,"activeCount":189,"soonestReadout":38},[469],{"nctId":36,"briefTitle":37,"status":108,"phases":470,"primaryCompletion":38,"completion":308,"start":309,"enrollment":181,"conditions":471,"interventions":472},[86],[311],[39,313,314,315],{"trials":474,"activeCount":96},[],{"trials":476,"activeCount":96},[],{"trials":478,"activeCount":96},[],{"intervention":480,"totalTrials":189,"cells":481},"chidamide, regorafenib, and iparomlimab\u002Ftuvonralimab",{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":483,"activeCount":96},[],{"trials":485,"activeCount":96},[],{"trials":487,"activeCount":189,"soonestReadout":110},[488],{"nctId":489,"briefTitle":490,"status":108,"phases":491,"primaryCompletion":110,"completion":449,"start":112,"enrollment":222,"conditions":492,"interventions":495},"NCT06930118","The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.",[86],[493,494],"Advanced Colorectal Cancer in the Third-line Treatment and Beyond","pMMR\u002FMSS Advanced Colorectal Cancer",[480],{"trials":497,"activeCount":96},[],{"trials":499,"activeCount":96},[],{"trials":501,"activeCount":96},[],{"intervention":44,"totalTrials":189,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":505,"activeCount":96},[],{"trials":507,"activeCount":96},[],{"trials":509,"activeCount":189,"soonestReadout":43},[510],{"nctId":41,"briefTitle":42,"status":108,"phases":511,"primaryCompletion":43,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":519},[86],"2024-12-31","2020-02-10",24,[516,33,517,518],"Gastric Cancer","Anlotinib","Toripalimab",[44],{"trials":521,"activeCount":96},[],{"trials":523,"activeCount":96},[],{"trials":525,"activeCount":96},[],{"intervention":328,"totalTrials":189,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":529,"activeCount":96},[],{"trials":531,"activeCount":96},[],{"trials":533,"activeCount":189,"soonestReadout":320},[534],{"nctId":317,"briefTitle":318,"status":171,"phases":535,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":536,"interventions":537},[86],[324,325,326],[328,329,39,313],{"trials":539,"activeCount":96},[],{"trials":541,"activeCount":96},[],{"trials":543,"activeCount":96},[],{"intervention":329,"totalTrials":189,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":547,"activeCount":96},[],{"trials":549,"activeCount":96},[],{"trials":551,"activeCount":189,"soonestReadout":320},[552],{"nctId":317,"briefTitle":318,"status":171,"phases":553,"primaryCompletion":320,"completion":320,"start":321,"enrollment":322,"conditions":554,"interventions":555},[86],[324,325,326],[328,329,39,313],{"trials":557,"activeCount":96},[],{"trials":559,"activeCount":96},[],{"trials":561,"activeCount":96},[],{"intervention":563,"totalTrials":189,"cells":564},"Injection of MSC303",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":566,"activeCount":96},[],{"trials":568,"activeCount":96},[],{"trials":570,"activeCount":189,"soonestReadout":575},[571],{"nctId":572,"briefTitle":573,"status":171,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":390,"conditions":578,"interventions":581},"NCT07000292","MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.",[85,86],"2026-05-20","2027-02-20","2025-06-20",[579,580],"Lupus Nephritis (LN)","ANCA-Associated Glomerulonephritis",[563],{"trials":583,"activeCount":96},[],{"trials":585,"activeCount":96},[],{"trials":587,"activeCount":96},[],{"intervention":589,"totalTrials":189,"cells":590},"FOLFIRI + Vemurafenib + Cetuximab",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":609,"PHASE4":611,"NA":613},{"trials":592,"activeCount":96},[],{"trials":594,"activeCount":96},[],{"trials":596,"activeCount":189,"soonestReadout":601},[597],{"nctId":598,"briefTitle":599,"status":108,"phases":600,"primaryCompletion":601,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":607},"NCT06603376","Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer",[86],"2026-08-31","2026-12-31","2024-09-01",75,[606],"Colorectal Carcinoma",[589,608],"FOLFIRI ± Bevacizumab",{"trials":610,"activeCount":96},[],{"trials":612,"activeCount":96},[],{"trials":614,"activeCount":96},[],{"intervention":608,"totalTrials":189,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":627,"PHASE4":629,"NA":631},{"trials":618,"activeCount":96},[],{"trials":620,"activeCount":96},[],{"trials":622,"activeCount":189,"soonestReadout":601},[623],{"nctId":598,"briefTitle":599,"status":108,"phases":624,"primaryCompletion":601,"completion":602,"start":603,"enrollment":604,"conditions":625,"interventions":626},[86],[606],[589,608],{"trials":628,"activeCount":96},[],{"trials":630,"activeCount":96},[],{"trials":632,"activeCount":96},[],{"intervention":634,"totalTrials":189,"cells":635},"Alverine Citrate",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":652,"PHASE4":654,"NA":656},{"trials":637,"activeCount":96},[],{"trials":639,"activeCount":96},[],{"trials":641,"activeCount":189,"soonestReadout":647},[642],{"nctId":643,"briefTitle":644,"status":645,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":651},"NCT05508633","The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study","ENROLLING_BY_INVITATION",[86],"2025-12","2022-10-28",20,[296],[634],{"trials":653,"activeCount":96},[],{"trials":655,"activeCount":96},[],{"trials":657,"activeCount":96},[],{"intervention":68,"totalTrials":189,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":661,"activeCount":96},[],{"trials":663,"activeCount":96},[],{"trials":665,"activeCount":189,"soonestReadout":67},[666],{"nctId":65,"briefTitle":66,"status":108,"phases":667,"primaryCompletion":67,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},[85,86],"2025-12-30","2024-07-16",40,[672],"Post-Infectious Cough",[68,674],"Normal saline nebulization combined with the compound methoxyphenamine",{"trials":676,"activeCount":96},[],{"trials":678,"activeCount":96},[],{"trials":680,"activeCount":96},[],{"intervention":674,"totalTrials":189,"cells":682},{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":684,"activeCount":96},[],{"trials":686,"activeCount":96},[],{"trials":688,"activeCount":189,"soonestReadout":67},[689],{"nctId":65,"briefTitle":66,"status":108,"phases":690,"primaryCompletion":67,"completion":668,"start":669,"enrollment":670,"conditions":691,"interventions":692},[85,86],[672],[68,674],{"trials":694,"activeCount":96},[],{"trials":696,"activeCount":96},[],{"trials":698,"activeCount":96},[],{"intervention":700,"totalTrials":189,"cells":701},"anlotinib and sintilimab",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":703,"activeCount":96},[],{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":189,"soonestReadout":712},[708],{"nctId":709,"briefTitle":710,"status":108,"phases":711,"primaryCompletion":712,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT07398326","Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer",[86],"2027-12-31","2028-12-31","2026-02-24",37,[18],[700],{"trials":719,"activeCount":96},[],{"trials":721,"activeCount":96},[],{"trials":723,"activeCount":96},[],{"intervention":725,"totalTrials":189,"cells":726},"PSMA-UCAR T",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":728,"activeCount":96},[],{"trials":730,"activeCount":189,"soonestReadout":736},[731],{"nctId":732,"briefTitle":733,"status":734,"phases":735,"primaryCompletion":736,"completion":737,"start":738,"enrollment":29,"conditions":739,"interventions":743},"NCT06895811","Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC","ACTIVE_NOT_RECRUITING",[85],"2026-07","2026-11","2025-03-27",[740,741,742],"Metastatic Prostate Cancer","Castration-resistant Prostate Cancer","Metastatic Castration-resistant Prostate Cancer",[725],{"trials":745,"activeCount":96},[],{"trials":747,"activeCount":96},[],{"trials":749,"activeCount":96},[],{"trials":751,"activeCount":96},[],{"intervention":753,"totalTrials":138,"cells":754},"HNF4α srRNA",{"EARLY_PHASE1":755,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":783},{"trials":756,"activeCount":138,"soonestReadout":761},[757,766],{"nctId":758,"briefTitle":759,"status":108,"phases":760,"primaryCompletion":761,"completion":736,"start":762,"enrollment":16,"conditions":763,"interventions":765},"NCT06583993","A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients",[84],"2026-05","2024-11-07",[764],"Intrahepatic Cholangiocarcinoma",[753],{"nctId":767,"briefTitle":768,"status":108,"phases":769,"primaryCompletion":736,"completion":770,"start":771,"enrollment":16,"conditions":772,"interventions":774},"NCT06621173","A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α SrRNA in Treating Metastatic CRC Patients",[84],"2026-09","2024-11-12",[773],"Metastatic Colorectal Cancer (mCRC)",[753],{"trials":776,"activeCount":96},[],{"trials":778,"activeCount":96},[],{"trials":780,"activeCount":96},[],{"trials":782,"activeCount":96},[],{"trials":784,"activeCount":96},[],{"intervention":786,"totalTrials":24,"cells":787},"Rifaximin",{"EARLY_PHASE1":788,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":837},{"trials":789,"activeCount":189,"soonestReadout":712},[790],{"nctId":791,"briefTitle":792,"status":108,"phases":793,"primaryCompletion":712,"completion":712,"start":794,"enrollment":670,"conditions":795,"interventions":797},"NCT07185932","Efficacy and Safety of Rifaximin in Treating MAFLD",[84],"2024-08-10",[796],"Metabolic-associated Fatty Liver Disease",[786],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"trials":803,"activeCount":96},[],{"trials":805,"activeCount":96},[806,816,827],{"nctId":807,"briefTitle":808,"status":809,"phases":810,"primaryCompletion":811,"completion":811,"start":812,"enrollment":670,"conditions":813,"interventions":815},"NCT03077217","Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy","COMPLETED",[88],"2020-05-31","2017-05-01",[814],"Covert Hepatic Encephalopathy",[786],{"nctId":817,"briefTitle":818,"status":289,"phases":819,"primaryCompletion":820,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT02074280","Rifaximin Predicts the Complications of Decompensated Cirrhosis",[88],"2014-06","2014-12","2013-10",250,[28],[826],"rifaximin",{"nctId":828,"briefTitle":829,"status":289,"phases":830,"primaryCompletion":831,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":836},"NCT02190357","Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial",[88],"2018-08","2019-08","2014-08",200,[28],[786],{"trials":838,"activeCount":96},[],{"intervention":840,"totalTrials":138,"cells":841},"CD-801",{"EARLY_PHASE1":842,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":843,"activeCount":189,"soonestReadout":857},[844,853],{"nctId":845,"briefTitle":846,"status":809,"phases":847,"primaryCompletion":848,"completion":848,"start":849,"enrollment":138,"conditions":850,"interventions":852},"NCT06092112","A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma",[84],"2024-04-29","2023-10-13",[851],"Advanced Hepatocellular Carcinoma",[840],{"nctId":854,"briefTitle":855,"status":108,"phases":856,"primaryCompletion":857,"completion":414,"start":858,"enrollment":715,"conditions":859,"interventions":860},"NCT06418659","A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients",[84],"2026-04","2024-10-12",[851],[840],{"trials":862,"activeCount":96},[],{"trials":864,"activeCount":96},[],{"trials":866,"activeCount":96},[],{"trials":868,"activeCount":96},[],{"trials":870,"activeCount":96},[],{"intervention":872,"totalTrials":189,"cells":873},"CAR-T cells",{"EARLY_PHASE1":874,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":894},{"trials":875,"activeCount":189,"soonestReadout":880},[876],{"nctId":877,"briefTitle":878,"status":108,"phases":879,"primaryCompletion":880,"completion":712,"start":881,"enrollment":514,"conditions":882,"interventions":885},"NCT06718270","a Study of CT0596 in Relapsed\u002FRefractory Multiple Myeloma and Relapsed\u002FRefractory Plasma Cell Leukemia",[84],"2027-01-03","2024-12-11",[883,884],"Relapsed\u002FRefractory Multiple Myeloma","Relapsed\u002FRefractory Plasma Cell Leukemia",[872],{"trials":887,"activeCount":96},[],{"trials":889,"activeCount":96},[],{"trials":891,"activeCount":96},[],{"trials":893,"activeCount":96},[],{"trials":895,"activeCount":96},[],{"intervention":897,"totalTrials":189,"cells":898},"Standard Endocrine Therapy",{"EARLY_PHASE1":899,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":900,"activeCount":189,"soonestReadout":905},[901],{"nctId":902,"briefTitle":903,"status":171,"phases":904,"primaryCompletion":905,"completion":906,"start":416,"enrollment":670,"conditions":907,"interventions":911},"NCT07389174","Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer",[84],"2027-01","2027-06",[908,909,910],"mHSPC","mHNPC","Prostate Cancer Adenocarcinoma",[897],{"trials":913,"activeCount":96},[],{"trials":915,"activeCount":96},[],{"trials":917,"activeCount":96},[],{"trials":919,"activeCount":96},[],{"trials":921,"activeCount":96},[],{"intervention":923,"totalTrials":189,"cells":924},"anti-CD70-CAR-T cells",{"EARLY_PHASE1":925,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":926,"activeCount":189,"soonestReadout":931},[927],{"nctId":928,"briefTitle":929,"status":108,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":16,"conditions":933,"interventions":935},"NCT06586658","Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed\u002FMetastatic CD70+ Inoperable Renal Cells",[84],"2027-07-16","2024-09-06",[934],"Renal Cell Carcinoma",[923],{"trials":937,"activeCount":96},[],{"trials":939,"activeCount":96},[],{"trials":941,"activeCount":96},[],{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":96},[],{"intervention":947,"totalTrials":189,"cells":948},"Creon（Pancreatin Enteric-coated Capsules）",{"EARLY_PHASE1":949,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":950,"activeCount":189,"soonestReadout":602},[951],{"nctId":952,"briefTitle":953,"status":108,"phases":954,"primaryCompletion":602,"completion":955,"start":956,"enrollment":294,"conditions":957,"interventions":959},"NCT07314489","A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis",[84],"2035-12-31","2025-04-01",[958],"Chronic Pancreatitis Pancreatic Exocrine Insufficiency Blood Glucose",[947],{"trials":961,"activeCount":96},[],{"trials":963,"activeCount":96},[],{"trials":965,"activeCount":96},[],{"trials":967,"activeCount":96},[],{"trials":969,"activeCount":96},[],{"intervention":971,"totalTrials":189,"cells":972},"MTS109",{"EARLY_PHASE1":973,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":974,"activeCount":189,"soonestReadout":979},[975],{"nctId":976,"briefTitle":977,"status":108,"phases":978,"primaryCompletion":979,"completion":980,"start":981,"enrollment":334,"conditions":982,"interventions":988},"NCT07526350","MTS109 in Patients With Refractory Autoimmune Diseases",[84],"2028-04-01","2029-04-01","2026-03-24",[983,984,985,986,987],"Systemic Lupus Erythematosus","Idiopathic Inflammatory Myopathies","Systemic Sclerosis (SSc)","ANCA-Associated Vasculitis (AAV)","Sjogren's Syndrome (SS)",[971],{"trials":990,"activeCount":96},[],{"trials":992,"activeCount":96},[],{"trials":994,"activeCount":96},[],{"trials":996,"activeCount":96},[],{"trials":998,"activeCount":96},[],{"intervention":421,"totalTrials":189,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":1002,"activeCount":189,"soonestReadout":414},[1003],{"nctId":411,"briefTitle":412,"status":171,"phases":1004,"primaryCompletion":414,"completion":415,"start":416,"enrollment":417,"conditions":1005,"interventions":1006},[84],[419],[338,421],{"trials":1008,"activeCount":96},[],{"trials":1010,"activeCount":96},[],{"trials":1012,"activeCount":96},[],{"trials":1014,"activeCount":96},[],{"trials":1016,"activeCount":96},[],{"intervention":1018,"totalTrials":189,"cells":1019},"anti-IGF-1R mAb",{"EARLY_PHASE1":1020,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1040},{"trials":1021,"activeCount":189,"soonestReadout":1026},[1022],{"nctId":1023,"briefTitle":1024,"status":734,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1031},"NCT06866548","Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer",[84],"2025-11-11","2028-11","2025-03-10",7,[419],[1018],{"trials":1033,"activeCount":96},[],{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[],{"trials":1039,"activeCount":96},[],{"trials":1041,"activeCount":96},[],{"intervention":1043,"totalTrials":189,"cells":1044},"Enhanced autologous PSMA-CAR T",{"EARLY_PHASE1":1045,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1046,"activeCount":189,"soonestReadout":761},[1047],{"nctId":1048,"briefTitle":1049,"status":734,"phases":1050,"primaryCompletion":761,"completion":414,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1054},"NCT06228404","Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC",[84],"2024-03-03",18,[742,741],[1043],{"trials":1056,"activeCount":96},[],{"trials":1058,"activeCount":96},[],{"trials":1060,"activeCount":96},[],{"trials":1062,"activeCount":96},[],{"trials":1064,"activeCount":96},[],{"intervention":1066,"totalTrials":189,"cells":1067},"Chimeric antigen receptor modified T cells",{"EARLY_PHASE1":1068,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1069,"activeCount":189,"soonestReadout":1074},[1070],{"nctId":1071,"briefTitle":1072,"status":108,"phases":1073,"primaryCompletion":1074,"completion":1074,"start":1075,"enrollment":417,"conditions":1076,"interventions":1077},"NCT06407947","Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma",[84],"2027-06-03","2024-06-06",[15],[1066],{"trials":1079,"activeCount":96},[],{"trials":1081,"activeCount":96},[],{"trials":1083,"activeCount":96},[],{"trials":1085,"activeCount":96},[],{"trials":1087,"activeCount":96},[],{"intervention":1089,"totalTrials":189,"cells":1090},"Rifaximin-α",{"EARLY_PHASE1":1091,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1092,"activeCount":189,"soonestReadout":712},[1093],{"nctId":1094,"briefTitle":1095,"status":108,"phases":1096,"primaryCompletion":712,"completion":712,"start":1097,"enrollment":222,"conditions":1098,"interventions":1100},"NCT07381257","Efficacy and Safety of Rifaximin-α in Treating MASLD",[84],"2026-01-15",[1099],"Metabolic Dysfunction-Associated Steatotic Liver Disease",[1089],{"trials":1102,"activeCount":96},[],{"trials":1104,"activeCount":96},[],{"trials":1106,"activeCount":96},[],{"trials":1108,"activeCount":96},[],{"trials":1110,"activeCount":96},[],{"intervention":63,"totalTrials":189,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1129},{"trials":1114,"activeCount":189,"soonestReadout":62},[1115],{"nctId":60,"briefTitle":61,"status":734,"phases":1116,"primaryCompletion":62,"completion":62,"start":1117,"enrollment":649,"conditions":1118,"interventions":1120},[84],"2023-04-28",[15,1119],"Primary Plasma Cell Leukemia",[63],{"trials":1122,"activeCount":96},[],{"trials":1124,"activeCount":96},[],{"trials":1126,"activeCount":96},[],{"trials":1128,"activeCount":96},[],{"trials":1130,"activeCount":96},[],{"intervention":1132,"totalTrials":189,"cells":1133},"CD-GA-102",{"EARLY_PHASE1":1134,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1135,"activeCount":189,"soonestReadout":415},[1136],{"nctId":1137,"briefTitle":1138,"status":108,"phases":1139,"primaryCompletion":415,"completion":415,"start":1140,"enrollment":649,"conditions":1141,"interventions":1145},"NCT07050394","A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer",[84],"2025-06-10",[1142,1143,1144],"Colorectal Cancer Metastatic","Colorectal Cancer Recurrent","Colorectal Cancer Stage IV",[1132],{"trials":1147,"activeCount":96},[],{"trials":1149,"activeCount":96},[],{"trials":1151,"activeCount":96},[],{"trials":1153,"activeCount":96},[],{"trials":1155,"activeCount":96},[],{"intervention":1157,"totalTrials":189,"cells":1158},"hiSCs",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1160,"activeCount":96},[],{"trials":1162,"activeCount":96},[],{"trials":1164,"activeCount":96},[],{"trials":1166,"activeCount":96},[],{"trials":1168,"activeCount":96},[],{"trials":1170,"activeCount":189,"soonestReadout":1175},[1171],{"nctId":1172,"briefTitle":1173,"status":108,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":334,"conditions":1178,"interventions":1180},"NCT06947746","HiSCs in the Treatment of Rheumatoid Arthritis",[89],"2026-06-01","2027-04-01","2025-05-01",[1179],"Rheumatoid Arthritis (RA)",[1157],{"intervention":49,"totalTrials":189,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1191,"NA":1193},{"trials":1184,"activeCount":96},[],{"trials":1186,"activeCount":96},[],{"trials":1188,"activeCount":96},[],{"trials":1190,"activeCount":96},[],{"trials":1192,"activeCount":96},[],{"trials":1194,"activeCount":189,"soonestReadout":48},[1195],{"nctId":46,"briefTitle":47,"status":171,"phases":1196,"primaryCompletion":48,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1202},[89],"2027-01-28","2024-01-28",39,[1201],"Advanced Solid Tumors With Neuroendocrine Differentiation",[49],{"intervention":1204,"totalTrials":189,"cells":1205},"human umbilical cord mesenchymal stem cells",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1207,"activeCount":96},[],{"trials":1209,"activeCount":96},[],{"trials":1211,"activeCount":96},[],{"trials":1213,"activeCount":96},[],{"trials":1215,"activeCount":96},[],{"trials":1217,"activeCount":189,"soonestReadout":1222},[1218],{"nctId":1219,"briefTitle":1220,"status":108,"phases":1221,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1227},"NCT06751199","UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes",[89],"2026-07-30","2026-12-01","2024-12-30",16,[21],[1204,1228],"allogeneic islet",{"intervention":1228,"totalTrials":189,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1232,"activeCount":96},[],{"trials":1234,"activeCount":96},[],{"trials":1236,"activeCount":96},[],{"trials":1238,"activeCount":96},[],{"trials":1240,"activeCount":96},[],{"trials":1242,"activeCount":189,"soonestReadout":1222},[1243],{"nctId":1219,"briefTitle":1220,"status":108,"phases":1244,"primaryCompletion":1222,"completion":1223,"start":1224,"enrollment":1225,"conditions":1245,"interventions":1246},[89],[21],[1204,1228],{"intervention":1248,"totalTrials":189,"cells":1249},"active folate",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1251,"activeCount":96},[],{"trials":1253,"activeCount":96},[],{"trials":1255,"activeCount":96},[],{"trials":1257,"activeCount":96},[],{"trials":1259,"activeCount":96},[],{"trials":1261,"activeCount":189,"soonestReadout":857},[1262],{"nctId":1263,"briefTitle":1264,"status":171,"phases":1265,"primaryCompletion":857,"completion":1266,"start":1267,"enrollment":1268,"conditions":1269,"interventions":1271},"NCT06930144","5-MTHF Supplementation for Treatment of Type 1 Diabetes Patients",[89],"2027-04","2025-04",34,[1270],"Type 1 Diabetes Mellitus",[1248],{"intervention":1273,"totalTrials":189,"cells":1274},"Denosumab 60 mg\u002Fml Injectable Solution [Prolia]",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1297},{"trials":1276,"activeCount":96},[],{"trials":1278,"activeCount":96},[],{"trials":1280,"activeCount":96},[],{"trials":1282,"activeCount":96},[],{"trials":1284,"activeCount":96},[1285],{"nctId":1286,"briefTitle":1287,"status":289,"phases":1288,"primaryCompletion":389,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1295},"NCT05203588","Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion",[88],"2023-10","2021-10-09",116,[1293,1294],"Osteoporosis","Fusion of Spine, Lumbar Region",[1273,1296],"calcium and vitamin D",{"trials":1298,"activeCount":96},[],{"intervention":1296,"totalTrials":189,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1315},{"trials":1302,"activeCount":96},[],{"trials":1304,"activeCount":96},[],{"trials":1306,"activeCount":96},[],{"trials":1308,"activeCount":96},[],{"trials":1310,"activeCount":96},[1311],{"nctId":1286,"briefTitle":1287,"status":289,"phases":1312,"primaryCompletion":389,"completion":1289,"start":1290,"enrollment":1291,"conditions":1313,"interventions":1314},[88],[1293,1294],[1273,1296],{"trials":1316,"activeCount":96},[],{"intervention":1318,"totalTrials":189,"cells":1319},"Fosinopril",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1326,"PHASE4":1328,"NA":1342},{"trials":1321,"activeCount":96},[],{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":96},[],{"trials":1327,"activeCount":96},[],{"trials":1329,"activeCount":96},[1330],{"nctId":1331,"briefTitle":1332,"status":289,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1339},"NCT02646397","Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension",[88],"2017-12","2016-02",508,[1338],"Chronic Kidney Disease",[1318,1340,1341],"Benidipine","Hydrochlorothiazide",{"trials":1343,"activeCount":96},[],{"intervention":1340,"totalTrials":189,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1360},{"trials":1347,"activeCount":96},[],{"trials":1349,"activeCount":96},[],{"trials":1351,"activeCount":96},[],{"trials":1353,"activeCount":96},[],{"trials":1355,"activeCount":96},[1356],{"nctId":1331,"briefTitle":1332,"status":289,"phases":1357,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1358,"interventions":1359},[88],[1338],[1318,1340,1341],{"trials":1361,"activeCount":96},[],{"intervention":1341,"totalTrials":189,"cells":1363},{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1378},{"trials":1365,"activeCount":96},[],{"trials":1367,"activeCount":96},[],{"trials":1369,"activeCount":96},[],{"trials":1371,"activeCount":96},[],{"trials":1373,"activeCount":96},[1374],{"nctId":1331,"briefTitle":1332,"status":289,"phases":1375,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1376,"interventions":1377},[88],[1338],[1318,1340,1341],{"trials":1379,"activeCount":96},[],{"intervention":1381,"totalTrials":189,"cells":1382},"IVIG",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1404},{"trials":1384,"activeCount":96},[],{"trials":1386,"activeCount":96},[],{"trials":1388,"activeCount":96},[],{"trials":1390,"activeCount":96},[],{"trials":1392,"activeCount":96},[1393],{"nctId":1394,"briefTitle":1395,"status":289,"phases":1396,"primaryCompletion":1397,"completion":603,"start":1398,"enrollment":670,"conditions":1399,"interventions":1403},"NCT05799716","Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections",[88],"2024-04-01","2023-04-01",[1400,1401,1402],"Viremia","Bacteremia","Acute Rejection of Renal Transplant",[1381],{"trials":1405,"activeCount":96},[],{"intervention":1407,"totalTrials":189,"cells":1408},"Palonosetron Hydrochloride",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1417,"NA":1430},{"trials":1410,"activeCount":96},[],{"trials":1412,"activeCount":96},[],{"trials":1414,"activeCount":96},[],{"trials":1416,"activeCount":96},[],{"trials":1418,"activeCount":96},[1419],{"nctId":1420,"briefTitle":1421,"status":809,"phases":1422,"primaryCompletion":1423,"start":1424,"enrollment":1425,"conditions":1426,"interventions":1429},"NCT01481831","Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting",[88],"2012-08","2011-07",599,[1427,1428],"Neoplasms","Chemotherapy-Induced Nausea and Vomiting",[1407,1407],{"trials":1431,"activeCount":96},[],{"intervention":1433,"totalTrials":189,"cells":1434},"Entecavir",{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1443,"NA":1456},{"trials":1436,"activeCount":96},[],{"trials":1438,"activeCount":96},[],{"trials":1440,"activeCount":96},[],{"trials":1442,"activeCount":96},[],{"trials":1444,"activeCount":96},[1445],{"nctId":1446,"briefTitle":1447,"status":289,"phases":1448,"primaryCompletion":1449,"completion":1450,"start":1451,"enrollment":834,"conditions":1452,"interventions":1455},"NCT00663182","Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis",[88],"2010-12","2012-12","2008-01",[1453,1454],"Hepatitis B Virus","Decompensated Cirrhosis",[1433],{"trials":1457,"activeCount":96},[],{"intervention":1459,"totalTrials":189,"cells":1460},"Triptolide-Containing Formulation",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1479,"NA":1481},{"trials":1462,"activeCount":96},[],{"trials":1464,"activeCount":96},[],{"trials":1466,"activeCount":96},[],{"trials":1468,"activeCount":96},[1469],{"nctId":1470,"briefTitle":1471,"status":289,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1478},"NCT02115659","Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[87],"2016-05","2014-04",100,[1477],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[1459],{"trials":1480,"activeCount":96},[],{"trials":1482,"activeCount":96},[],{"intervention":1484,"totalTrials":9,"cells":1485},"GC012F",{"EARLY_PHASE1":1486,"PHASE1":1513,"PHASE2":1522,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1487,"activeCount":96},[1488,1495,1504],{"nctId":1489,"briefTitle":1490,"status":289,"phases":1491,"primaryCompletion":72,"completion":72,"start":1492,"enrollment":1052,"conditions":1493,"interventions":1494},"NCT05840107","Study of FasT CAR-T GC012F Injection NDMM Patients",[84],"2023-05-04",[15],[1484],{"nctId":1496,"briefTitle":1497,"status":289,"phases":1498,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":334,"conditions":1502,"interventions":1503},"NCT04617704","BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma",[84],"2021-12-31","2022-02-01","2021-12-01",[15],[1484],{"nctId":1505,"briefTitle":1506,"status":289,"phases":1507,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":334,"conditions":1511,"interventions":1512},"NCT04236011","BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory\u002FRelapsed Multiple Myeloma",[84],"2022-07-31","2022-12-31","2020-01-16",[15],[1484],{"trials":1514,"activeCount":96},[1515],{"nctId":1516,"briefTitle":1517,"status":289,"phases":1518,"primaryCompletion":333,"completion":333,"start":1519,"enrollment":16,"conditions":1520,"interventions":1521},"NCT05412329","Study of Dual Targeted CD19\u002FBCMA FASTCART GC012F in Relapsed\u002F Refractory Multiple Myeloma",[85],"2022-06-13",[15],[1484],{"trials":1523,"activeCount":96},[1524],{"nctId":1525,"briefTitle":1526,"status":289,"phases":1527,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":649,"conditions":1530,"interventions":1531},"NCT04935580","Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients",[85,86],"2023-07-01","2021-06-28",[15],[1484],{"trials":1533,"activeCount":96},[],{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":96},[],{"intervention":1539,"totalTrials":189,"cells":1540},"Regorafenib and PD-1 inhibitor",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1542,"activeCount":96},[],{"trials":1544,"activeCount":96},[],{"trials":1546,"activeCount":96},[1547],{"nctId":1548,"briefTitle":1549,"status":289,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT04110093","Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer",[85,86],"2021-08-31","2019-03-01",120,[18,33],[1539],{"trials":1557,"activeCount":96},[],{"trials":1559,"activeCount":96},[],{"trials":1561,"activeCount":96},[],{"intervention":1563,"totalTrials":189,"cells":1564},"PAD Followed by ASCT",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1566,"activeCount":96},[],{"trials":1568,"activeCount":96},[],{"trials":1570,"activeCount":96},[1571],{"nctId":1572,"briefTitle":1573,"status":809,"phases":1574,"primaryCompletion":1575,"completion":1576,"start":1450,"enrollment":1052,"conditions":1577,"interventions":1578},"NCT01852799","A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma",[86],"2016-09","2017-01",[15],[1563],{"trials":1580,"activeCount":96},[],{"trials":1582,"activeCount":96},[],{"trials":1584,"activeCount":96},[],{"intervention":1586,"totalTrials":189,"cells":1587},"Zanubrutinib",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1605,"PHASE4":1607,"NA":1609},{"trials":1589,"activeCount":96},[],{"trials":1591,"activeCount":96},[],{"trials":1593,"activeCount":96},[1594],{"nctId":1595,"briefTitle":1596,"status":289,"phases":1597,"primaryCompletion":956,"completion":1598,"start":1599,"enrollment":222,"conditions":1600,"interventions":1602},"NCT05979948","A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine\u002FRituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia",[86],"2025-12-01","2023-08-01",[1601],"Waldenström's Macroglobulinemia",[1586,1603,1604],"Bendamustine","Rituximab",{"trials":1606,"activeCount":96},[],{"trials":1608,"activeCount":96},[],{"trials":1610,"activeCount":96},[],{"intervention":1603,"totalTrials":189,"cells":1612},{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1623,"PHASE4":1625,"NA":1627},{"trials":1614,"activeCount":96},[],{"trials":1616,"activeCount":96},[],{"trials":1618,"activeCount":96},[1619],{"nctId":1595,"briefTitle":1596,"status":289,"phases":1620,"primaryCompletion":956,"completion":1598,"start":1599,"enrollment":222,"conditions":1621,"interventions":1622},[86],[1601],[1586,1603,1604],{"trials":1624,"activeCount":96},[],{"trials":1626,"activeCount":96},[],{"trials":1628,"activeCount":96},[],{"intervention":1604,"totalTrials":189,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1635,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1632,"activeCount":96},[],{"trials":1634,"activeCount":96},[],{"trials":1636,"activeCount":96},[1637],{"nctId":1595,"briefTitle":1596,"status":289,"phases":1638,"primaryCompletion":956,"completion":1598,"start":1599,"enrollment":222,"conditions":1639,"interventions":1640},[86],[1601],[1586,1603,1604],{"trials":1642,"activeCount":96},[],{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[],{"intervention":1648,"totalTrials":189,"cells":1649},"TNFα Monoclonal Antibody",{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1651,"activeCount":96},[],{"trials":1653,"activeCount":96},[],{"trials":1655,"activeCount":96},[1656],{"nctId":1657,"briefTitle":1658,"status":289,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1665},"NCT04988425","TNFα Monoclonal Antibody for Acute Spinal Cord Injury",[85,86],"2023-08-30","2022-09-01",90,[1664],"Spinal Cord Injuries",[1648,1666,1667],"Methylprednisolone","Saline",{"trials":1669,"activeCount":96},[],{"trials":1671,"activeCount":96},[],{"trials":1673,"activeCount":96},[],{"intervention":1667,"totalTrials":189,"cells":1675},{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1677,"activeCount":96},[],{"trials":1679,"activeCount":96},[],{"trials":1681,"activeCount":96},[1682],{"nctId":1657,"briefTitle":1658,"status":289,"phases":1683,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1684,"interventions":1685},[85,86],[1664],[1648,1666,1667],{"trials":1687,"activeCount":96},[],{"trials":1689,"activeCount":96},[],{"trials":1691,"activeCount":96},[],{"intervention":1693,"totalTrials":189,"cells":1694},"EGFR antibody and Chemotherapy",{"EARLY_PHASE1":1695,"PHASE1":1697,"PHASE2":1699,"PHASE3":1711,"PHASE4":1713,"NA":1715},{"trials":1696,"activeCount":96},[],{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":96},[1701],{"nctId":1702,"briefTitle":1703,"status":289,"phases":1704,"primaryCompletion":1551,"completion":1499,"start":1705,"enrollment":1475,"conditions":1706,"interventions":1709},"NCT04136600","EGFR Monoclonal Antibody for Advanced Gastric Cancer",[86],"2019-07-01",[516,1707,1708],"Cetuximab","Nimotuzumab",[1693,1710],"Chemotherapy",{"trials":1712,"activeCount":96},[],{"trials":1714,"activeCount":96},[],{"trials":1716,"activeCount":96},[],{"intervention":1710,"totalTrials":189,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1720,"activeCount":96},[],{"trials":1722,"activeCount":96},[],{"trials":1724,"activeCount":96},[1725],{"nctId":1702,"briefTitle":1703,"status":289,"phases":1726,"primaryCompletion":1551,"completion":1499,"start":1705,"enrollment":1475,"conditions":1727,"interventions":1728},[86],[516,1707,1708],[1693,1710],{"trials":1730,"activeCount":96},[],{"trials":1732,"activeCount":96},[],{"trials":1734,"activeCount":96},[],{"intervention":1736,"totalTrials":189,"cells":1737},"Irinotecan",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1739,"activeCount":96},[],{"trials":1741,"activeCount":96},[],{"trials":1743,"activeCount":96},[1744],{"nctId":1745,"briefTitle":1746,"status":289,"phases":1747,"primaryCompletion":1748,"completion":1749,"start":1748,"enrollment":1662,"conditions":1750,"interventions":1751},"NCT03329183","High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28",[86],"2019-03","2022-03",[18],[1736],{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"intervention":1759,"totalTrials":189,"cells":1760},"Anlotinib plus Sintilimab",{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1779,"PHASE4":1781,"NA":1783},{"trials":1762,"activeCount":96},[],{"trials":1764,"activeCount":96},[],{"trials":1766,"activeCount":96},[1767],{"nctId":1768,"briefTitle":1769,"status":809,"phases":1770,"primaryCompletion":1771,"completion":1772,"start":1773,"enrollment":181,"conditions":1774,"interventions":1778},"NCT04271813","Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)",[86],"2023-09-30","2024-02-29","2020-06-01",[18,33,517,1775,1776,1777],"Sintilimab","Chemo-free Therapy","First-line Treatment",[1759],{"trials":1780,"activeCount":96},[],{"trials":1782,"activeCount":96},[],{"trials":1784,"activeCount":96},[],{"intervention":394,"totalTrials":189,"cells":1786},{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1797,"PHASE4":1799,"NA":1801},{"trials":1788,"activeCount":96},[],{"trials":1790,"activeCount":96},[],{"trials":1792,"activeCount":96},[1793],{"nctId":384,"briefTitle":385,"status":289,"phases":1794,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":1795,"interventions":1796},[86],[392],[394,314,395],{"trials":1798,"activeCount":96},[],{"trials":1800,"activeCount":96},[],{"trials":1802,"activeCount":96},[],{"intervention":395,"totalTrials":189,"cells":1804},{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1806,"activeCount":96},[],{"trials":1808,"activeCount":96},[],{"trials":1810,"activeCount":96},[1811],{"nctId":384,"briefTitle":385,"status":289,"phases":1812,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":1813,"interventions":1814},[86],[392],[394,314,395],{"trials":1816,"activeCount":96},[],{"trials":1818,"activeCount":96},[],{"trials":1820,"activeCount":96},[],{"intervention":1822,"totalTrials":189,"cells":1823},"Autologous bone marrow-derived mononuclear cells",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1825,"activeCount":96},[],{"trials":1827,"activeCount":96},[],{"trials":1829,"activeCount":96},[1830],{"nctId":1831,"briefTitle":1832,"status":289,"phases":1833,"primaryCompletion":1834,"completion":1835,"start":1836,"enrollment":1837,"conditions":1838,"interventions":1840},"NCT04528550","Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury",[86],"2023-10-01","2023-12-01","2020-10-01",45,[1839],"Spinal Cord Injury",[1822],{"trials":1842,"activeCount":96},[],{"trials":1844,"activeCount":96},[],{"trials":1846,"activeCount":96},[],{"intervention":1848,"totalTrials":189,"cells":1849},"Vemurafenib",{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1863,"PHASE4":1865,"NA":1867},{"trials":1851,"activeCount":96},[],{"trials":1853,"activeCount":96},[],{"trials":1855,"activeCount":96},[1856],{"nctId":1857,"briefTitle":1858,"status":289,"phases":1859,"primaryCompletion":1501,"completion":1509,"start":1860,"enrollment":181,"conditions":1861,"interventions":1862},"NCT03727763","Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)",[86],"2018-10-08",[18],[1848,1707],{"trials":1864,"activeCount":96},[],{"trials":1866,"activeCount":96},[],{"trials":1868,"activeCount":96},[],{"intervention":1707,"totalTrials":189,"cells":1870},{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1872,"activeCount":96},[],{"trials":1874,"activeCount":96},[],{"trials":1876,"activeCount":96},[1877],{"nctId":1857,"briefTitle":1858,"status":289,"phases":1878,"primaryCompletion":1501,"completion":1509,"start":1860,"enrollment":181,"conditions":1879,"interventions":1880},[86],[18],[1848,1707],{"trials":1882,"activeCount":96},[],{"trials":1884,"activeCount":96},[],{"trials":1886,"activeCount":96},[],{"intervention":1888,"totalTrials":189,"cells":1889},"Arsenic Trioxide",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1891,"activeCount":96},[],{"trials":1893,"activeCount":96},[],{"trials":1895,"activeCount":96},[1896],{"nctId":1897,"briefTitle":1898,"status":289,"phases":1899,"primaryCompletion":1551,"completion":1900,"start":1901,"enrollment":181,"conditions":1902,"interventions":1906},"NCT04695223","Arsenic Trioxide for Structural p53 Mutations",[86],"2021-10-31","2021-01-01",[1888,1903,1904,1905],"p53 Mutations","Refractory Cancer","Intractable Cancer",[1888],{"trials":1908,"activeCount":96},[],{"trials":1910,"activeCount":96},[],{"trials":1912,"activeCount":96},[],{"intervention":1914,"totalTrials":189,"cells":1915},"Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α",{"EARLY_PHASE1":1916,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1917,"activeCount":96},[1918],{"nctId":1919,"briefTitle":1920,"status":1921,"phases":1922,"primaryCompletion":1923,"completion":1923,"start":1924,"enrollment":96,"conditions":1925,"interventions":1926},"NCT06572189","The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma","WITHDRAWN",[84],"2026-07-31","2024-08-28",[764],[1914],{"trials":1928,"activeCount":96},[],{"trials":1930,"activeCount":96},[],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[],{"intervention":1938,"totalTrials":138,"cells":1939},"methylprednisolone",{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1944,"PHASE3":1950,"PHASE4":1952,"NA":1954},{"trials":1941,"activeCount":96},[],{"trials":1943,"activeCount":96},[],{"trials":1945,"activeCount":96},[1946],{"nctId":1657,"briefTitle":1658,"status":289,"phases":1947,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1948,"interventions":1949},[85,86],[1664],[1648,1666,1667],{"trials":1951,"activeCount":96},[],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[1956],{"nctId":1957,"briefTitle":1958,"status":289,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1961,"enrollment":138,"conditions":1962,"interventions":1964},"NCT02711982","Surgery for Traumatic Optic Neuropathy",[89],"2020-12","2010-01",[1963],"Traumatic Optic Neuropathy",[1938],{"intervention":1966,"totalTrials":189,"cells":1967},"intervention group",{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1976,"NA":1978},{"trials":1969,"activeCount":96},[],{"trials":1971,"activeCount":96},[],{"trials":1973,"activeCount":96},[],{"trials":1975,"activeCount":96},[],{"trials":1977,"activeCount":96},[],{"trials":1979,"activeCount":96},[1980],{"nctId":1981,"briefTitle":1982,"status":289,"phases":1983,"primaryCompletion":1499,"completion":1499,"start":1984,"enrollment":1985,"conditions":1986,"interventions":1988},"NCT04088526","Survey and Reduction of Mortality in Peridialysis Uremic Patients Via Intervention of Risk Factors",[89],"2016-01-01",2500,[1987],"End Stage Renal Disease on Dialysis",[1966],{"intervention":1990,"totalTrials":189,"cells":1991},"Vonopazan +Amoxicillin",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":1998,"PHASE4":2000,"NA":2002},{"trials":1993,"activeCount":96},[],{"trials":1995,"activeCount":96},[],{"trials":1997,"activeCount":96},[],{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[],{"trials":2003,"activeCount":96},[2004],{"nctId":2005,"briefTitle":2006,"status":289,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2012,"interventions":2014},"NCT06004401","The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori",[89],"2025-08-31","2025-12-31","2023-08-20",400,[2013],"The Eradication Rate of Helicobacter Pylori",[1990,2015,2016,2017],"Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin","Vonopazan +Minocycline","Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin",{"intervention":2015,"totalTrials":189,"cells":2019},{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2021,"activeCount":96},[],{"trials":2023,"activeCount":96},[],{"trials":2025,"activeCount":96},[],{"trials":2027,"activeCount":96},[],{"trials":2029,"activeCount":96},[],{"trials":2031,"activeCount":96},[2032],{"nctId":2005,"briefTitle":2006,"status":289,"phases":2033,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2034,"interventions":2035},[89],[2013],[1990,2015,2016,2017],{"intervention":2016,"totalTrials":189,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2039,"activeCount":96},[],{"trials":2041,"activeCount":96},[],{"trials":2043,"activeCount":96},[],{"trials":2045,"activeCount":96},[],{"trials":2047,"activeCount":96},[],{"trials":2049,"activeCount":96},[2050],{"nctId":2005,"briefTitle":2006,"status":289,"phases":2051,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2052,"interventions":2053},[89],[2013],[1990,2015,2016,2017],{"intervention":2017,"totalTrials":189,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2057,"activeCount":96},[],{"trials":2059,"activeCount":96},[],{"trials":2061,"activeCount":96},[],{"trials":2063,"activeCount":96},[],{"trials":2065,"activeCount":96},[],{"trials":2067,"activeCount":96},[2068],{"nctId":2005,"briefTitle":2006,"status":289,"phases":2069,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2070,"interventions":2071},[89],[2013],[1990,2015,2016,2017],{"intervention":2073,"totalTrials":189,"cells":2074},"Pyrotinib",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[],{"trials":2080,"activeCount":96},[],{"trials":2082,"activeCount":96},[],{"trials":2084,"activeCount":96},[],{"trials":2086,"activeCount":96},[2087],{"nctId":2088,"briefTitle":2089,"status":289,"phases":2090,"primaryCompletion":1705,"completion":2091,"start":1705,"enrollment":181,"conditions":2092,"interventions":2093},"NCT03843749","Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.",[89],"2022-07-01",[18],[2073],{"intervention":2095,"totalTrials":189,"cells":2096},"UCMSCs",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2107},{"trials":2098,"activeCount":96},[],{"trials":2100,"activeCount":96},[],{"trials":2102,"activeCount":96},[],{"trials":2104,"activeCount":96},[],{"trials":2106,"activeCount":96},[],{"trials":2108,"activeCount":96},[2109],{"nctId":2110,"briefTitle":2111,"status":289,"phases":2112,"primaryCompletion":72,"completion":2113,"start":2114,"enrollment":514,"conditions":2115,"interventions":2117},"NCT06407297","UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes",[89],"2026-05-01","2024-05-23",[2116],"Newly Diagnosed Type 1 Diabetes Mellitus",[2095],{"intervention":2119,"totalTrials":189,"cells":2120},"Medication Treatment",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2122,"activeCount":96},[],{"trials":2124,"activeCount":96},[],{"trials":2126,"activeCount":96},[],{"trials":2128,"activeCount":96},[],{"trials":2130,"activeCount":96},[],{"trials":2132,"activeCount":96},[2133],{"nctId":2134,"briefTitle":2135,"status":289,"phases":2136,"primaryCompletion":2137,"completion":2137,"start":2138,"enrollment":2139,"conditions":2140,"interventions":2142},"NCT02983747","Autologous Platelet Rich Plasma on Low Back Pain",[89],"2022-12-30","2019-11-01",112,[2141],"Low Back Pain",[2119],{"intervention":517,"totalTrials":189,"cells":2144},{"EARLY_PHASE1":2145,"PHASE1":2147,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2146,"activeCount":96},[],{"trials":2148,"activeCount":96},[],{"trials":2150,"activeCount":96},[],{"trials":2152,"activeCount":96},[],{"trials":2154,"activeCount":96},[],{"trials":2156,"activeCount":96},[2157],{"nctId":2158,"briefTitle":2159,"status":289,"phases":2160,"primaryCompletion":2161,"completion":1528,"start":1705,"enrollment":181,"conditions":2162,"interventions":2164},"NCT03929965","Anlotinib in Advanced Solid Tumors With FGFR Alteration",[89],"2020-07-01",[2163],"Advanced Solid Tumor",[517],{"intervention":2166,"totalTrials":189,"cells":2167},"Anti-CD19-CD3E-CAR-T cells",{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2174,"PHASE4":2176,"NA":2178},{"trials":2169,"activeCount":96},[],{"trials":2171,"activeCount":96},[],{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[],{"trials":2177,"activeCount":96},[],{"trials":2179,"activeCount":96},[2180],{"nctId":2181,"briefTitle":2182,"status":289,"phases":2183,"primaryCompletion":123,"completion":2184,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2194},"NCT06373081","Anti-CD19-CD3E-CAR-T Cells in Relapsed\u002FRefractory Autoimmune Disease",[89],"2026-04-15","2024-04-20",6,[2188,2189,2190,2191,2192,2193],"Systemic Lupus Erythematosus (SLE)","Sjogren's Syndrome","Systemic Sclerosis","Inflammatory Myopathy","ANCA Associated Vasculitis","Antiphospholipid Syndrome",[2166]]